tbuckley/cabot-search huggingface dataset:
Efficacy of radioimmunotherapy-based conditioning with high-dose chemotherapy and autologous stem cell transplantation for transformed lymphoma.
Authors: Amrita Y. Krishnan, Marielle Wondergem, Joycelynne Palmer, Avichai Shimoni, Andrew Antony Raubitschek, Auayporn Nademanee, Otto Visser, Jose M Zijlstra, Nicole Tsai, Arnon Nagler, Neil Martin Kogut, Jennifer Simpson, Stephen J. Forman
Journal: Journal of Clinical Oncology (2013)

8556 Background: Transformed non-Hodgkin lymphoma (TF NHL) has a poor prognosis with median survival of 7-20 months. Studies have suggested the benefit of HDC. The series by Eide showed 47%, 5yr OS in 47 pts treated with HDC and ASCT (Br J Hem 2011). Our multicenter experience with RIT plus HDC (Yttrium 90 ibritumomab tiuxetan plus BEAM; carmustine, etoposide, cytarabine, melphalan "ZBEAM") demonstrated the safety and efficacy of the regimen in diffuse large cell lymphoma (DLCL). Therefore, the regimen was explored in other subtypes of NHL. Herein we report the outcome of 57 pts with TF NHL treated with ZBEAM conditioning and ASCT at three centers (City of Hope USA n=20, VUMC the Netherlands n=31, Chaim Sheba Med Center, Israel n=6.) between 2003- 2011. Methods: Histological confirmation of transformation was defined as dx of DLCL in pts with either a prior history or concomitant dx of follicular NHL. Results: Median age at ASCT was 59.6 yrs (range 41-69). Median number of prior regimens 2 (range 1-6), all pts received rituximab in at least one regimen. Disease status at ASCT: 1st CR 29, 1stPR 7,1st rel 9, IF 5, 2nd CR 5, 2nd rel 1, &gt;3CR 1. Median time from TF NHL dx to ASCT was 7.7 mo (range 2.8-116). Pts engrafted white cells at median of 12 days (range 8-33). Non relapse mortality was 3.5%. There were two second malignancies: 1 MDS and 1 SCC Skin. Median f/u for living pts was 29 mo (range 7-100). Two year PFS was 69.67% (95%CI 59.39 - 77.83) and OS 90.29% (95% CI: 79.63 - 95.52). On univariate analysis, number of prior regimens, time from TF NHL dx to ASCT and history of marrow involvement were not significant for PFS and OS. Disease status at ASCT was significant for PFS in 1st CR vs relapse disease ( p=0.03) The relapsed pts had a significant increase in risk of relapse/progression or death post ASCT compared to the 1CR patients. [HR = 2.9, (95% CI: 1.07 - 7.9)]. Conclusions: ZBEAM conditioning with ASCT is an active treatment for pts with TF NHL, and is particularly efficacious as consolidation for pts in 1st CR.
Angiogenesis biomarker study of a phase II trial of pazopanib (P) in recurrent or persistent ovarian (EOC), peritoneal (PPC), or fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study.
Authors: Jose Antonio Lopez-Guerrero, Ana Oaknin, Antonio González-Martín, Yolanda García, Silvia Catot, Cristina Caballero, Jesus Garcia-Donas, Isabel Bover, Ana Santaballa, Eva Guerra Alia, Beatriz Pardo, Laura Vidal Boixader, Raul Marquez, Víctor Freixinos, Ignacio Romero, Amparo Ruiz-Sauri, Andres Poveda
Journal: Journal of Clinical Oncology (2012)

e15575 Background: Angiogenesis is essential to tumor growth, invasion, and metastasis in EOC. The aim of this study was to identify angiogenic biomarkers to predict response to P, a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit, in a clinical phase II trial. Methods: We analyzed a series of 20 out of 25 women enrolled in a GEICO Phase II trial that studied the Clinical Benefit Rate (CBR) of P in platinum-resistant EOC, PPC and FTC (results will be presented in an additional abstract). Formalin-fixed, paraffin-embedded tumors at diagnosis were evaluated for the microvessel density (MVD) by using CD31 immunostaining and the Image Pro-Plus 7.0 Image Analysis System (Media-Cybernetics). In addition, several angiogenic factors were evaluated by means of immunohistochemistry (IHC) on tissue arrays sections, and quantitative real-time PCR (qRT-PCR) using the Human Angiogenesis Arrays (Applied Biosystems). Serum samples were also collected at different moments of the treatment schedule and a panel of 14 citokines and growth factors were evaluated using the Luminex technology (Millipore). Results: Fifteen (75%) of the tumors were high grade serous EOC. Eight patients (40%) showed a CBR on treatment.MVD analysis, (number of vessels/mm 2 ) was 2025 (835-3242) and 2410 (1449-3543) in patients with and without CBR respectively (p=0.278). IHC showed very low expression of angiogenesis-related factors including VEGF and VEGFRs, PDGF and PDGFRs, HIF and pAKT. Expression analysis by qRT-PCR and serum levels of cytokines and growth factors revealed no statistical differences between patients with and without CBR. Conclusions: No predictive biomarkers of CBR to P in platinum-resistant EOC could be identified in a population of patients with low expression level of angiogenic factors at diagnosis.
COLANGIOPANCREATOGRAFÍA GUIADA POR ECOENDOSCOPIA CON AZUL DE METILENO EN PATOLOGÍA BILIOPANCREÁTICA BENIGNA DESPUÉS DE CPRE FALLIDA: UNA ESTRATEGIA EFICAZ
Authors: CF Consiglieri Alvarado, S Albines, M De La Hera, E Garcia-Recio, L Secanella, N Pelaez, J Busquets, JB Gornals
Journal: Endoscopy (2015)

Introducción: La CPRE es el procedimiento Gold Standard en la terapéutica endoscópica de la vía biliar. Cuando ésta falla (5 – 10%, ej. papila no identificable), las alternativas son: nuevo intento de CPRE, CTPH o quirúrgico. Sin embargo, en los últimos años la evolución de la USE intervencionista ha ofrecido una nueva alternativa para acceder al conducto biliar o pancreático. El uso de colorante para la identificación del orificio papilar ha sido descrito en casos esporádicos de canulación ampular fallida.
Clinical effectiveness of recombinant adenovirus-p53 combined with radiotherapy in advanced soft tissue sarcoma: A report of 37 cases.
Authors: Jianhao Geng, Shaowen Xiao, Shanwen Zhang, Changqing Liu, Yongheng Li, Jiafu Ji, Zhiwei Fang, Yan Sun, Xing Su, Yong Cai, Gang Xu, Dongming Li, Guangying Zhu, Bo Xu
Journal: Journal of Clinical Oncology (2014)

e21514 Background: To evaluate the efficacy and safety for the treatment of advanced soft tissue sarcoma with recombinant human adenovirus p53 (rAd-p53, Gendicine) injection and radiotherapy. Methods: From October 1, 2001, to May 1, 2013, 37 advanced soft tissue sarcoma patients have been treated with rAd-p53 plus radiotherapy. Gene therapy: multipoint injection of rAd-p53 within the neoplasm was given to head and neck as well as abdominal and pelvic tumor by ultrasound guided and to pulmonary metastatic lesion by CT guided. rAd-p53 was injected or perfused 1 × 1012 VP / 2 ml once a week for 3-16 weeks, and the average was 7 ± 2 weeks. Radiotherapy: radiotherapy was delivered 48-72 hours after the first rAd-p53 perfusion to a cumulative dose of 16-70 Gy / 8-35 fractioins / 2-7 weeks (average dose, 52.0 ± 5.0 Gy). Results: The rates of CR, PR, SD accounted for 8.1% (3/37), 43.2% (16/37) and 48.6% (18/37), respectively. All 18 patients of SD achieved the purpose of relieving pain and reducing local symptoms. The median follow-up time was 21 months (range, 6 to 116 months). The median overall survival (OS) and time to progression (TTP) times were 18.0 months and 13.6 months, respectively. The 1-,2-, 3- and 5-year OS rates were 56.8% (21/37), 21.6% (8/37), 16.2% (6/37) and 10.8% (4/37), respectively. Among all 39 patients who accepted rAd-p53 injection for several times, there were no significant adverse events except temporary fever. Conclusions: It is effective and safe for soft tissue sarcoma patients using the treatment of rAd-p53 weekly injection with concurrent radiotherapy. The rAd-p53 is a potential gene therapy drug for the treatment of soft tissue sarcoma.
Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2: A SWOG phase II trial (S0341)
Authors: P. J. Hesketh, K. Chansky, A. J. Wozniak, P. Mack, P. N. Lara, W. A. Franklin, F. R. Hirsch, J. Crowley, D. R. Gandara
Journal: Journal of Clinical Oncology (2007)

7536 Background: Patients (pts) with advanced NSCLC and PS 2 have an inferior survival compared with good PS pts. Single agent and combination chemotherapy have been used with modest success with toxicity often limiting treatment. Targeted agents such as the EGFR tyrosine kinase inhibitor erlotinib (E) offer an alternative which may confer comparable benefit with better tolerance. This phase II trial of E in unselected chemotherapy-naive pts with advanced NSCLC and PS 2 was performed to obtain preliminary data regarding efficacy and EGFR biology in this pt population, and to set the stage for a subsequent randomized trial of E vs.chemotherapy, in pts selected for EGFR expression. Methods: Eligibility: stage IIIB (pleural effusion)/IV NSCLC; measurable disease; PS 2; no prior chemotherapy/biologic treatment for NSCLC. Treatment: E 150 mg orally daily. Molecular correlative studies:EGFR protein expression (IHC), gene copy (FISH), mutation analysis. Results: Pts: 82; 73 eligible; 72 fully evaluable; age (median) 74.4; M/F 47%/53%; current/former smoker 91%; stage IIIB/V 12%/88%; adenoca 54%. Treatment was well tolerated. Five pts (7%) had a grade 4 toxicity (fatigue 3 pts; dyspnea 2 pts). Most common grade 3 toxicities: fatigue 9 pts (13%); rash 7 pts (10%); diarrhea 5 pts (7%); anorexia 5 pts (7%). There was 1 possible treatment related death due to pneumonitis. One complete (1%) and 5 (7%) partial responses were noted. Stable disease was seen in 25 pts (35%) for an overall disease control rate (DCR) of 43% (31 pts). Progression free survival: 2.1 months (95% CI 1.5 –3.1); Median survival: 5.0 months (95 % CI 3.5 –7.3). One year survival: 22% (95% CI 12 –32%). Analysis of molecular correlates is ongoing. Conclusions: Single agent erlotinib is a well tolerated treatment for chemotherapy- naive patients with advanced NSCLC and PS 2 with an overall DCR of 43% and median survival of 5 months. These efficacy results are comparable to the outcome seen in SWOG trial S0027 in PS 2 pts employing sequential vinorelbine and docetaxel. We hypothesize that pt selection by an EGFR biomarker strategy will improve results with E, and that E will be superior to chemotherapy in this selected population.This trial design is under development within SWOG at present. [Table: see text]
Infectious complications after prostate needle biopsy: Predictors of bacteremia and sepsis.
Authors: Simpa Samuel Salami, Neeti Bagadiya, Michael J Schwartz, Louis R Kavoussi, Carl A. Olsson, Manish Arvind Vira
Journal: Journal of Clinical Oncology (2014)

e16035 Background: Transrectal ultrasound guided biopsy of the prostate (TRUSBX) remains as the gold standard for the diagnosis of prostate cancer. Recent studies have reported that 3-5% of men will suffer an infectious complication requiring hospitalization following TRUSBX. Our objective was to evaluate a large cohort of men hospitalized for post biopsy infection and determine which factors predict septic complications. Methods: Over a 3-year period, a total of 19,143 patients underwent TRUSBX at either a large community urology practice or academic urology department. Two hundred and thirty patients (1.2%) were admitted within 30 days post biopsy, of whom 96 were admitted to our health system hospitals for which hospital records were available. Demographic and clinical information obtained from patients’ charts were recorded in an IRB-approved database. Logistic regression was used to evaluate factors predicting bacteremia and sepsis in a multivariate model. Results: Mean presentation was 3.1 days following TRUSBX. The vast majority presented with fever (94%); some patients complained of gastrointestinal (GI) symptoms (42%), hematuria (34%), and dysuria (22%). Review of clinical outcomes revealed that 44% had positive blood cultures, 43% progressed to sepsis, and 17% progressed to septic shock. Analysis of risk factors demonstrated that these patients presented significantly sooner after TRUSBX (mean 1.9 vs 3.9 days, p=0.0018). On multivariate analysis, GI symptoms and Charlson comorbidity score were associated with significantly higher risk of progressing to sepsis or septic shock. In fact, men who presented with fever and GI symptoms were 3.4 times more likely to progress to sepsis as compared to men without these symptoms (p=0.0062). Interestingly, maximum temperature, white blood cell count, and history of diabetes were not statistically associated with risk of bacteremia or sepsis. Conclusions: Infection following TRUSBX is a serious and potentially lethal complication. A significant number of patients will progress to sepsis or septic shock. Men who present with GI symptoms (along with fever) and men with significant comorbidities are at highest risk for progression to sepsis.
Clinicopathologic characteristics of Lebanese patients under and over the age of 40 presenting with breast cancer at a single institution.
Authors: Ali Shamseddine, Sarah M Abu Kar, Raafat Alameddine, Ahmad Saleh, Sally Temraz, Deborah Mukherji, Nadim Majzoub, Hani Dimassi, Arafat Tfayli, Rami Mahfouz, Georges Nemer, Muhieddine A Seoud, Ghada El-hajj, Naji Saghir, Fouad Boulos
Journal: Journal of Clinical Oncology (2013)

e12525 Background: The objective of this study was to determine the clinicopathologic characteristics of Lebanese patients with breast cancer below 40 compared to those above 40 presenting to our institution. Methods: Using a cross-sectional study design, data were collected prospectively on a sample of 110 women newly diagnosed with breast cancer. Comparison between the groups was performed using Person Chi-square and Fishers exact test. Results: 28 patients were ≤ 40 years and 82 patients &gt;40 years. 75% and 76.5% of patients above and below 40 years respectively presented with stage I or II disease, more patients above 40 presented with stage I compared to those below 40 (32.4% vs 8% respectively). 50% of the younger age group presented with a grade 3 tumor; however, more than the half of the older group presented with grade 1 or 2. The older age group had a higher incidence of concurrent lobular and intraductal carcinoma (0 vs 6.4%). The younger age group was more likely to present with nodal involvement (57.1% vs. 48.45 for younger and older age groups respectively). Similar proportions of the two age groups stained positive for cyclin B1, p53, and VEGFR. All patients stained positive for PDGFR. Mean value of Ki-67 was 21.8% and 24%in younger and older age groups respectively. These differences were not statistically significant. Methylene Tetrahydrofolate Reductase (MTHFR) single nuccleotide polymorphism (SNP) T677T was detected in 21% of the older group compared to 5% of the younger population. Stratified to age Vitamin D receptor (VDR) SNP ApaI A/A was found in similar proportion in both groups (35% and 33.3% in younger and older group) while 30% and 41.3 % carried the vitamin D receptor (SNP) BSMI b/b in younger and older group respectively. Conclusions: No significant differences in the clinicopathologic characteristics examined between patients younger or older than 40 years were found in this sample. Analysis of a larger sample size including BRCA gene mutation analysis is planned to determine differences between age groups and possibly explain the higher incidence of breast cancer in the younger age group in our population.
Frequency of relapse over time based on baseline stage in esophageal cancer patients treated with definitive chemoradiation (DCRT).
Authors: Roopma Wadhwa, Lianchun Xiao, Kazuki Sudo, Takashi Taketa, Mariela A. Blum, Heath D. Skinner, Jeffrey H. Lee, Manoop S. Bhutani, Brian Weston, Ritsuko Komaki, David C. Rice, Stephen Swisher, Wayne Lewis Hofstetter, Jaffer A. Ajani
Journal: Journal of Clinical Oncology (2013)

e15013 Background: Evidence for definitive chemoradiotherapy (bimodality therapy [BMT]) has been established for patients with Esophageal and Gastroesophageal Junction cancers (EGEJC) who do not qualify for surgery. Frequency of relapse over time based on baseline clinical stage is not well described. Methods: We analyzed 276 patients with EGEJC who underwent BMT. All the patients had pre- and post- chemoradiation, endoscopic biopsy and imaging study. The type and timing of first relapse or persistent disease after BMT was analyzed using 12-month intervals and was grouped by the baseline stage. Multiple statistical methods were used. Results: For 276 patients, the median follow-up time was 53.0 months (95% confidence interval [CI], 47.3-58.7) and the median overall survival was 27.0months (95% CI, 20.7-33.3). A total of 184 (66.7%) patients had a persistent disease or relapse after BMT: 120 distant metastases (43.5% of 276) and 64 local-regional disease (23.2% of 276). The table below demonstrates that baseline clinical stage has a great deal of influence on the frequency and timing of relapse (see Table). Conclusions: These data demonstrate that relapse timing and patterns are associated with the baseline clinical stage. Our data can contribute to an evidence-based surveillance strategy.[Table: see text]
Recurrence and survival outcomes following percutaneous thermal ablation of oligometastatic melanoma.
Authors: Mariah Lei White, Thomas D Atwell, Anil Nicholas Kurup, Grant Schmit, Rickey Carter, Jennifer Geske, Lisa A. Kottschade, Matthew Stephen Block, Matthew R Callstrom, Svetomir Markovic
Journal: Journal of Clinical Oncology (2015)

e20040 Background: Focal treatment of melanoma metastases has been demonstrated to provide extended survival in a very select patient population. To our knowledge, percutaneous image-guided thermal ablation of metastatic lesions has not been described for patients with stage IV melanoma. Methods: All patients who underwent image-guided local thermal ablation of metastatic melanoma over an 11-year period (2002-2013) were retrospectively identified using an internally maintained clinical registry. Only patients with oligometastatic stage IV disease amenable to complete ablation of all clinical disease at the time of ablation were included in our analysis. Progression of disease was followed with contrast-enhanced CT, MRI or PET/CT for identification of local recurrence at the ablation site, recurrent organ specific and/or new metastatic disease outside the previously treated organ. Overall survival and median progression-free survival (including local recurrence at the ablation site, treated organ recurrence and new metastatic disease) were calculated. Results: Thirty-three patients with primary ocular or cutaneous melanoma had 67 metastases treated in the lungs, liver, bones or soft tissues. Thirteen (39.4%) patients were on systemic medical therapy at the time of the procedure. The median survival time was 3.8 years with 5-year estimated survival of 27.5% (95% Cl: 14.6 to 51.9%). Local recurrence at the ablation site developed in 15.1% (5/33) of patients and 13.4% of tumors (9/67). Median progression-free survival time was 4.4 months with estimated 1-year progression-free survival of 30.3% (95% Cl:18.1 to 50.8%). There were no major complications and no deaths within 30 days post procedure. Conclusions: We demonstrate that image-guided thermal ablation of metastatic melanoma amenable to complete ablation of all clinical disease confers a potential survival benefit with minimal risk.
Gene expression as a predictor of radiotherapy or chemoradiotherapy response in head and neck squamous cell carcinoma patients: A molecular approach.
Authors: Antonio Lopez-Pousa, Xavier Leon, Miquel Quer, Ana Quintana, Luis Vila, Mercedes Camacho, Ivana Sullivan, Oscar Gallego Rubio, Josep M. De Vega, Nuria Farre, Agust Barnadas
Journal: Journal of Clinical Oncology (2012)

5590 Background: There are not validated markers of radioresistance in patients with a head and neck squamous cell carcinoma (HNSCC). The objective of our study was to explore the relationship between response to radiotherapy and the expression at transcriptional level of a panel of genes related with the HNSCC carcinogenic process. Methods: The study group was 76 consecutive HNSCC patients treated with radiotherapy (n=51) or chemoradiotherapy (n=25) with curative intention, and a minimum follow-up of three years. Thirty-seven patients were T1-T2 tumors and 16 had an advanced tumor (T3-T4). Biopsy specimens were performed from the primary tumor before treatment and conveniently stored until processing. Expression of genes related with cell cycle (cyclin D1), apoptosis (Bcl-XL), angiogenesis (VEGF), inflammation (IL-8), and tissue invasiveness (MMP-2 and MMP-9) were examined using a RT-PCR method. The continuous value of the mRNA expression level was evaluated with a classification and regression tree (CRT) method, considering the local control of the disease achieved with radiotherapy as the dependent variable. Results: During the follow-up 26 patients (33.8%) had a local failure. The CRT method found a significant relationship between VEGF and MMP-9 expression and local control of the disease. According the expression level of VEGF and MMP-9 the patients were classified in three groups: the A group (n=19) defined by a low expression of VEGF, the B group (n=19) defined by a high expression of VEGF and a low expression of MMP-9 and the C group (n=38) defined by a high expression of both VEGF and MMP-9. The 5-year local recurrence free survival was: A group 94.7% (CI 95%: 84.7-100%), B group 83.3% (CI 95%: 66.1-100%), and C group 37.6% (CI 95%: 21.0-54.2%). There were significant differences in the local control of the disease according to the VEGF and MMP-9 expression values (test log rank, P&lt;0.0001). Conclusions: Expression of VEGF and MMP-9 genes may be a radiosensitivity marker for patients with HNSCC treated with radical intention. We didn’t find prognostic significance for other genes explored.
The role of early postoperative PET-CT in patients with pathological stage III colon cancer: Results from a large single institution study.
Authors: Assaf Moore, Irit Ben-Aharon, Ofer Purim, Gali Perl, Olga Ulitsky, Limor Amit, Yulia Kundel, Ron Lewin, Nir Wasserberg, Yael Asman, Hanoch Kashtan, Baruch Brenner
Journal: Journal of Clinical Oncology (2017)

562 Background: Current staging of patients (pts) with pathological stage III colon cancer is suboptimal; many pts still recur despite unremarkable preoperative staging work-up. We previously reported that early postoperative PET-CT can alter the stage and management of pts with high risk stage III colon cancer in up to 19% of patients. The aim of the current study was to expand the previous one to a larger cohort and to determine the role of early postoperative PET-CT in the general population of stage III colon cancer pts, regardless of their individual risk. Methods: A retrospective chart review of all consecutive pts with stage III colon cancer who underwent early postoperative PET-CT between 2007 and 2016. Demographic and clinicopathological data were collected. Results: 247 pts, 124 (50%) males, with a median age of 66 years (range, 30-92), were included. Pathological stage was IIIA, IIIB and IIIC in 18 (7.3%), 161 (65.1%) and 72 (29.1%) pts, respectively. The median number of lymph nodes retrieved was 15 (range, 6-64) and that of positive lymph nodes was 2 (range, 0-21). High FDG-uptake was observed in 52 (21.0%) pts, including 6 (2.4%) who had clear postoperative changes, 10 (4.0%) who had a false positive abnormal uptake of whom 6 underwent invasive diagnostic procedures. The PET-CT results modified the management of 36 pts (14.5%) who were found to have true positive findings: 30 (12.1%) were proven to have overt metastatic disease and in 6 (2.4%) a second primary was discovered. With the median follow-up of 39.0 months (range 7.2-98.4 months), of the 30 pts found to be metastatic, 10 (33.3%) underwent curative treatments and are currently with no evidence of disease (NED). Updated data, on more patients and a longer follow-up, will be presented at the meeting. Conclusions: Early postoperative PET-CT changed the staging and treatment of 14.5% of resected stage III pts, and has the potential for early detection of curable metastatic disease. We currently evaluate this strategy and its actual impact in a prospective trial.